Sign in
4

Changes in Ownership

MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0000899243-24-000266

Pres., R&D, and CMO sold 73,888 shares at an average $243.92 ($18,022,588)

  • Pres., R&D, and CMO acquired 73,888 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Taub Rebecca · Pres., R&D, and CMO

Table I: Non-derivative

22 lines
Date Transaction Shares Price Value Owned after D/I
2024-04-03 Exercise or conversion : show line 1 in the form 10b5-1 +27,845 $9.45 $263,135 486,844 D
2024-04-03 Sale : show line 2 in the form 10b5-1 −135 $242.00 $32,670 486,709 D
2024-04-03 Sale : show line 3 in the form 10b5-1 −2,634 $243.68 $641,866 484,075 D
2024-04-03 Sale : show line 4 in the form 10b5-1 −4,070 $244.68 $995,854 480,005 D
2024-04-03 Sale : show line 5 in the form 10b5-1 −18,917 $245.34 $4,641,014 461,088 D
2024-04-03 Sale : show line 6 in the form 10b5-1 −2,089 $246.32 $514,573 458,999 D
2024-04-04 Exercise or conversion : show line 7 in the form 10b5-1 +18,537 $9.45 $175,175 477,536 D
2024-04-04 Sale : show line 8 in the form 10b5-1 −4,200 $240.88 $1,011,679 473,336 D
Open-market sales · 73,888 sh · avg $243.92 · $18,022,588

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2024-04-03 Exercise or conversion : show line 23 in the form 10b5-1 Stock Option (Right to Buy) −27,845 125,283 D
2024-04-04 Exercise or conversion : show line 24 in the form 10b5-1 Stock Option (Right to Buy) −18,537 106,746 D
2024-04-05 Exercise or conversion : show line 25 in the form 10b5-1 Stock Option (Right to Buy) −27,506 79,240 D
Loading xslF345X05/doc4.xml…